Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;9(6):3836-3845.
doi: 10.1002/ehf2.14055. Epub 2022 Aug 10.

Prevalence and prognostic implications of reduced left ventricular ejection fraction among patients with STEMI in India

Michael J Hendrickson  1 , Sameer Arora  2 , Muthiah Vaduganathan  3 , Gregg C Fonarow  4 , Girish Mp  5 , Ankit Bansal  5 , Vishal Batra  5 , Shekhar Kunal  5 , Deepak L Bhatt  3 , Mohit Gupta  5 , Arman Qamar  6
Affiliations

Prevalence and prognostic implications of reduced left ventricular ejection fraction among patients with STEMI in India

Michael J Hendrickson et al. ESC Heart Fail. 2022 Dec.

Abstract

Aims: To describe clinical characteristics and outcomes for those with STEMI and reduced left ventricular ejection fraction (LVEF) in low-income and middle-income countries (LMICs).

Methods and results: Adults presenting with STEMI to two government-owned tertiary care centres in Delhi, India were prospectively enrolled in the North India ST-elevation myocardial infarction (NORIN-STEMI) registry. LVEF was evaluated at presentation and clinical characteristics were compared across LVEF categories. Overall, 3597 patients were included, of whom 468 (13%) had LVEF >50%, 1482 (41%) had mildly reduced LVEF (40-49%), 1357 (38%) had moderately reduced LVEF (30-39%), and 290 (8%) had severely reduced LVEF (<30%). Presentation delay >24 h, prior MI, and hyperlipidaemia were associated with decreasing LVEF category. Although most patients with reduced LVEF were discharged on appropriate guideline-directed therapies, adherence at 1 year was low (ACE inhibitor/ARB 91% to 41%, beta blocker 98% to 78%, aldosterone receptor antagonist 69% to 6%). After multivariable adjustment, a Cox regression model showed moderately reduced LVEF (HR 1.77, 95% CI 1.20, 2.60) and severely reduced LVEF (HR 3.63, 95% CI 2.41, 5.48) were associated with increased risk of all-cause mortality compared with LVEF ≥50%.

Conclusions: On presentation for STEMI, almost 90% of NORIN-STEMI participants had at least mildly reduced LVEF and almost half had LVEF <40%. Patients with LVEF <40% had significantly higher risk of mortality at 1 year, and adherence to guideline-directed therapies at 1 year was poor. Systematic initiatives to improve access to timely revascularization and guideline-directed therapies are essential in advancing STEMI care in LMICs.

Keywords: NORIN-STEMI; ST-elevation myocardial infarction; atherosclerotic cardiovascular disease; heart failure; left ventricular dysfunction.

PubMed Disclaimer

Conflict of interest statement

Dr. Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health, speaker engagements with Novartis, AstraZeneca, and Roche Diagnostics, and participates on clinical trial committees for studies sponsored by Galmed, Impulse Dynamics, Bayer AG, Novartis, and Occlutech. Dr. Bhatt discloses the following relationships ‐ Advisory Board: Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, Stasys; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, TobeSoft; Chair: Inaugural Chair, American Heart Association Quality Oversight Committee; Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (Chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Novartis, Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol‐Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE‐DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS‐II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), K2P (Co‐Chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co‐leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor), NCDR‐ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Research Funding: Abbott, Afimmune, Aker Biomarine, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Bristol‐Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, 89Bio; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease); Site Co‐Investigator: Abbott, Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Philips, Svelte; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Merck, Takeda. Dr Fonarow reports consulting for Abbott, Amgen, AstraZeneca, Bayer, Cytokinetics, Edwards, Janssen, Medtronic, Merck, and Novartis. The remaining authors report no disclosures, financial or otherwise.

Figures

Figure 1
Figure 1
Left ventricular ejection fraction at presentation in NORIN‐STEMI participants.
Figure 2
Figure 2
Time from symptom onset to healthcare presentation in NORIN‐STEMI participants, stratified by left ventricular ejection fraction at presentation.
Figure 3
Figure 3
Survival of adults by left ventricular ejection fraction at presentation in NORIN‐STEMI participants.
Figure 4
Figure 4
Adjusted odds ratios and 95% confidence intervals of decreasing left ventricular ejection fraction category for baseline characteristics in NORIN‐STEMI participants.
Figure 5
Figure 5
Central Illustration: Prevalence and prognostic significance of reduced left ventricular ejection fraction among patients with STEMI in North India.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Gheorghiade M, Bonow RO. Chronic heart failure in the United States: A manifestation of coronary artery disease. Circulation. 1998; 97: 282–289. - PubMed
    1. Lund LH, Mancini D. Heart failure in women. Med Clin North Am. 2004; 88: 1321–1345. - PubMed
    1. White HD, Cross DB, Elliott JM, Norris RM, Yee TW. Long‐term prognostic importance of patency of the infarct‐related coronary artery after thrombolytic therapy for acute myocardial infarction. Circulation. 1994; 89: 61–67. - PubMed
    1. Townsend N, Wilson L, Bhatnagar P, Wickramasinghe K, Rayner M, Nichols M. Cardiovascular disease in Europe: Epidemiological update 2016. Eur Heart J. 2016; 37: 3232–3245. - PubMed
    1. Jernberg T, Omerovic E, Hamilton E, Lindmark K, Desta L, Alfredsson J, Lundberg A, Kellerth T, Erlinge D. Prevalence and prognostic impact of left ventricular systolic dysfunction after acute myocardial infarction. Eur Heart J [Internet]. 2020. [cited 2021 Nov 4];41. Available from: https://academic.oup.com/eurheartj/article/doi/10.1093/ehjci/ehaa946.179... (Accessed 11/22/21). - DOI - PMC - PubMed

MeSH terms

Substances